阿斯利康&森松法玛度

10月28日，阿斯利康新加坡模块化工厂项目发货仪式在森松法玛度常熟制造基地举行。一批先进的制药模块化生产设施正式启航新加坡大士南（Tuas South）制造基地，标志着项目从模块制造阶段迈向现场建设新阶段。

阿斯利康项目总监Paul Si先生（左）

森松生命科技首席执行官汤卫华先生（右）

阿斯利康项目总监Paul Si先生

森松生命科技法玛度（中国）总经理李道全先生

森松法玛度承接阿斯利康新加坡基地核心楼栋——抗体偶联药物（ADC）厂房的设计及建造。面对项目体量大、交付周期紧、质量标准高、模块集成度高、国际协同复杂及运输条件严格等多重挑战，森松法玛度发挥模块化工程领域的专业优势，统筹设计、采购、制造、调试及国际物流等关键环节，与阿斯利康建立高效协同机制，推动跨区域、跨专业团队紧密配合。依托成熟的项目管理体系和国际化项目执行经验，团队遵循阿斯利康全球工程标准与质量要求，采用分批发货方式，使模块发运节奏与现场吊装计划精准匹配，实现现场吊装无缝衔接，有效解决大型模块运输限制问题，充分发挥工厂预制优势，大幅降低现场施工工作量，提升整体建设效率与质量可控性。

从模块制造启动到工厂FAT工作的完成，仅用不到六个月时间，森松法玛度高效完成关键里程碑节点，展现了在大型国际生物制药项目中的综合交付能力，也为后续现场建设及产能快速落地奠定了坚实基础。

森松生命科技法玛度（中国）总经理李道全先生表示，“阿斯利康新加坡项目是双方深化合作的重要成果，也是森松法玛度服务全球生物制药产业的又一标杆实践。项目顺利推进凝聚了双方团队的信任、协作与共同努力。森松法玛度携手阿斯利康，共同推动生物制药先进产能建设，为创新药物研发与生产提供坚实支撑。”

此次启航承载的不仅是一批模块化生产设施，更是阿斯利康与森松法玛度对创新、品质与合作的共同追求，是服务患者健康的共同使命。未来，森松法玛度将继续以专业工程能力连接全球创新资源，助力更多生物药成果加速转化为守护患者健康的现实力量。

关于森松法玛度

作为全球知名的模块化工厂和解决方案专业提供商，Pharmadule公司自1986年以来已成功交付了80多个制药和生物制药行业的生产设施，完成了超过300个工程设计和验证方案。公司拥有丰富的国际项目交付经验，熟悉不同地区的法规要求，不断为全球的制药和生物制药客户提供一系列工程和解决方案。2011年，Pharmadule公司成为森松集团的一员，森松法玛度的模块化工厂实现了厂房与工艺的完美结合，为客户提供更高品质更快速的整体解决方案。如需了解更多信息，请访问：www.pharmadule.com

Pharmadule Morimatsu Ships AstraZeneca Singapore Operations’s Modular Facility to Singapore

AstraZeneca&Pharmadule Morimatsu

On October 28th, a Shipment Ceremony for AstraZeneca Singapore Operations’ Modular Project was held at the Pharmadule Morimatsu Suzhou manufacturing site. A batch of advanced modular pharmaceutical manufacturing modules officially began its journey to AstraZeneca’s Tuas South manufacturing site in Singapore, marking the transition of the project from the manufacturing phase to the on-site construction phase.

Mr.Paul Si, Project Director of AstraZeneca（left）

Mr.Weihua Tang, CEO of Morimatsu LifeSciences（right）

Mr.Paul Si, Project Director of AstraZeneca

Mr.Daoquan Li, CEO of Morimatsu Pharmadule(China)

Pharmadule Morimatsu is responsible for the design and construction of the antibody drug conjugate (ADC) conjugation building, a core component of AstraZeneca' s Singapore Operations facility. Throughout project execution, the team successfully addressed multiple challenges, including the project's large scale, tight schedule, stringent quality requirements, high expectation of modular integration, complex international stakeholder coordination, and demanding logistics constraints. Leveraging its extensive expertise in modular engineering, Pharmadule Morimatsu coordinated critical project phases, including engineering, procurement, manufacturing, commissioning, and international logistics, while maintaining close collaboration with AstraZeneca through an efficient project governance framework that enabled seamless cross-functional and cross-regional teamwork.

Supported by a mature project management system and extensive international project delivery experience, the team executed the project in accordance with AstraZeneca's global engineering and quality standards. Through a carefully planned phased shipping strategy, module deliveries were precisely aligned with the site's lifting and installation schedule, ensuring smooth and uninterrupted onsite execution. This approach not only mitigated transportation constraints associated with large-scale modules but also maximized the benefits of offsite fabrication, significantly reducing onsite construction activities while improving overall project efficiency, quality control, and delivery certainty.

From the commencement of module fabrication to the completion of Factory Acceptance Testing (FAT), the project achieved this key shipment milestone in less than six months. This accomplishment demonstrates Pharmadule Morimatsu's comprehensive execution capabilities in delivering large-scale international biopharmaceutical projects and provides a solid foundation for the subsequent site construction phase and the rapid realization of future production capacity.

“

Mr.Daoquan Li, CEO of Morimatsu Pharmadule(China) stated: "The AstraZeneca Singapore project represents an important achievement in the deepening partnership between our two companies and stands as another benchmark project showcasing Pharmadule Morimatsu’s commitment to serving the global biopharmaceutical industry. The successful progress of the project reflects the trust, collaboration, and dedication shared by both teams. Together with AstraZeneca, we are advancing the development of world-class biopharmaceutical manufacturing capacity and providing strong support for the research, development, and production of innovative medicines."

This delivery represents more than the transportation of modular production facilities. It reflects the shared commitment of AstraZeneca and Pharmadule Morimatsu to innovation, quality, and collaboration, as well as a common mission to improve patient health. Looking ahead, Pharmadule Morimatsu will continue to connect global innovation through its engineering expertise, helping accelerate the transformation of biopharmaceutical breakthroughs into life-changing therapies that improve and protect lives around the world.

About Pharmadule Morimatsu

Since its establishment in 1986, Pharmadule(a member of Morimatsu Group since 2011) has delivered more than 90 production facilities in pharma and biopharma industries globally as well as completed more than 300 engineering designs and solution validations which demonstrates us as the integrated, holistic facility as well as core process equipment leading provider in the world. For more information about Pharmadule Morimatsu, please visit:www.pharmadule.com

关于森松生命科技

森松生命科技是森松国际控股有限公司（森松国际，股票代码：2155.HK）的重要业务板块之一，主要由上海森松制药设备工程有限公司、森松（苏州）生命科技有限公司、上海森松生物科技有限公司、上海森众生物技术有限公司、上海森纮科技有限公司、瑞士比欧生物工程公司、瑞典森松法玛度等公司及其附属公司组成。

我们专注于提供制药、生物制药、医美、快速消费品（含化妆品、食品、保健品等）、数据中心等领域的核心设备、工艺系统和数智化整体工厂解决方案及相应服务。公司拥有一支由工艺研发、工程设计、高端制造、验证咨询、生产执行、数智运维等多领域资深专家的精英团队。团队成员在制药、生物制药、医美、快消、数据中心等行业和领域拥有丰富的经验，熟悉不同产品的特性及工艺流程，能够针对客户的需求，从概念设计阶段起提供定制化的工艺解决方案，满足客户的个性化需求。

森松生命科技已构建起全球战略布局，在全球不同国家和地区建立先进研发、设计中心和制造基地的同时，形成了覆盖欧美、亚太及新兴市场的完善服务网络。公司国际化专业团队已成功为40多个国家和地区提供定制化解决方案，在全球项目执行方面积累了丰富经验。

作为掌握核心工艺技术、模块化建造及数智化工厂技术的跨国企业，森松生命科技致力于满足全球制药、生物制药、医美、快消、数据中心等行业和领域对生产装备的需求。公司通过不断创新和优化，助力国内企业加速实现核心和高端装备的国产替代战略布局，推动行业发展。同时，公司积极拓展海外市场，深化“全球化”业务开拓战略，为全球生命科学及相关行业贡献森松力量。